Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 6;247:116728. doi: 10.1016/j.carbpol.2020.116728

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 4 — TGC161 raises CD4⁺ T cell counts in complement-mediated cytotoxicity killing model. Mice were treated with monoclonal CD4 antibodies (150 μg/per mouse) by intraperitoneal injection. TGC161 (400 mg/kg) were administrated by gavage once a day for 15, 20, 25 days (n = 4). (A) CD4⁺ T cell percentage in peripheral blood. (B and C) Analysis of CD4⁺ T cell percentage and counts. Data were presented as mean ± standard error of the mean.